Common NOTCH3 Variants and Cerebral Small-Vessel Disease by Jacobs, Loes et al.
1482
Cerebral small-vessel disease (SVD) accounts for nearly one quarter of all ischemic strokes and is an impor-
tant cause of dementia. Lacunar infarction and white mat-
ter hyperintensities (WMH) on MRI are lesions commonly 
seen in SVD. Genetic factors have been suggested to play 
an important role in SVD.1–3 Several monogenic causes of 
SVD have been described, the most common of which is 
cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL). CADASIL 
is caused by mutations in the NOTCH3 gene, and among 
the main features are recurrent ischemic strokes and white 
matter lesions on MRI.4 Besides CADASIL causing muta-
tions, it has been suggested that more common variants in 
NOTCH3 may also contribute to the risk of sporadic SVD.5 
This study in a community-dwelling elderly cohort, the 
Austrian Stroke Prevention Study, found 4 common single 
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nucleotide polymorphism (SNP) polymorphisms at the 
NOTCH3 gene (rs10404382, rs1043994, rs10423702, and 
rs1043997) to be associated with the presence of WMH. 
However, these associations seemed to be restricted to 
hypertensive subjects. In contrast, another study in 120 
patients with lacunar stroke found no association between 
2 common NOTCH3 SNPs (rs3815188 and rs1043994) 
and the presence of WMH.6 One other study investigated 
the association between common NOTCH3 variation and 
ischemic stroke in white patients.7 This study identified the 
SNP rs78501403 to be associated with ischemic stroke, 
but power was lacking to investigate this association in the 
SVD subtype. Lacunar infarcts are small and frequently not 
seen on computed tomography; therefore, MRI is important 
for accurate diagnosis.
To test the hypothesis that common NOTCH3 variation 
is associated with SVD, we investigated the association of 
common variants in NOTCH3 with both clinical and MRI-
confirmed lacunar stroke and with WMH lesion volume quan-
tified on MRI.
Methods
Lacunar Stroke Population
Lacunar stroke cases were obtained from cohorts from the United 
Kingdom, Germany, and Belgium (n=1350; aged, 60 years [SD, 11]; 
68% men; Table I in the online-only Data Supplement). Lacunar 
stroke was defined as a clinical lacunar syndrome8 with a compatible 
lesion on MRI (subcortical infarct ≤15 mm in diameter). Exclusion 
criteria were as follows: stenosis >50% in the extra- or intracranial 
cerebral vessels; cardioembolic source of stroke, defined according 
to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) cri-
teria9 as high or moderate probability; subcortical infarct >15 mm 
in diameter, as these can be caused by embolic mechanisms (stri-
atocapsular infarcts); any other specific cause of stroke (eg, lupus 
anticoagulant, cerebral vasculitis, and dissection). A description of 
all cohorts is given in the online-only Data Supplement. Controls 
(n=7397) for the United Kingdom and German analyses were de-
rived from population cohorts and were therefore not confirmed 
to be stroke free. Belgian controls were ascertained from the local 
population.
SVD stroke subtype, classified using the TOAST criteria,9 and leu-
koaraiosis grading using the semiquantitative Fazekas scale was per-
formed with central review of all MRI scans by 1 physician (H.S.M.). 
The Fazekas scale has been shown to reflect pathological severity of 
SVD in a postmortem validation study.10 In addition, lacunar infarcts 
were determined as high signal lesions <1.5 cm diameter on acute 
diffusion-weighted imaging sequences or fluid attenuated inversion 
recovery or low signal lesions on T1 sequences.
A preplanned secondary analysis was performed in those SVD 
cases with confluent leukoaraiosis (Fazekas grade >2 or multiple la-
cunar infarcts (n=717; 53%), as cases of CADASIL present with this 
phenotype, and compared with the controls (n=7397).
WMH Volumes Population
The WMH volumes population (n=3670) was derived from isch-
emic stroke cohorts from United Kingdom, Italy, Belgium, Germany, 
Australia, and United Stated (Table II in the online-only Data 
Supplement). Inclusion criteria were as follows: aged >18 years, 
self-reported European ancestry, and a diagnosis of ischemic stroke. 
Exclusion criteria were CADASIL, vasculitis, and demyelinating 
and mitochondrial disorders. For the present study, we included all 
available patients with ischemic stroke from each cohort who met 
the inclusion and exclusion criteria and had MRI and genome-wide 
association study data available. MRI scans were acquired as a part 
of routine clinical practice for evaluation of ischemic stroke. Fluid 
attenuated inversion recovery sequences were primarily used for leu-
koaraiosis analysis; however, in their absence, T2 sequences were 
used. All scans were quantitatively graded to obtain a WMH volume, 
which was normalized for intracranial volume. WMH volume was 
measured in the hemisphere contralateral to the infarcts and doubled 
to obtain whole brain volumes. All neuroimaging analyses have been 
previously described.11
Genotyping
Genotyping of all cohorts was performed on commercially available 
arrays from Affymetrix or Illumina. All cohorts performed extensive 
quality control steps before imputation, removing SNPs showing 
significant departure from Hardy-Weinberg equilibrium, high levels 
of missingness or low minor allele frequency. Individuals were re-
moved that did not segregate with Hapmap II European populations 
based on ancestry informative principal component (PC) analysis us-
ing EIGENSTRAT software package  or multidimensional scaling in 
PLINK software package.12,13 In addition, individuals with high levels 
of missingness or heterozygosity were excluded. All data sets were 
imputed to 1000 genomes integrated variant set (March 2012) using 
IMPUTE version 2.14
Lacunar Stroke Analyses
We analyzed binary case/control status for each lacunar stroke 
population using a score test, as implemented in SNPTEST ver-
sion 2.5. Imputed genotype probabilities were taken into account 
using a missing data likelihood score test or an expectation-maxi-
mization method for SNPs with low mean allele frequency or high 
uncertainty. The first 2 ancestry informative PCs, age and sex were 
included as covariates in the model where possible (sex and PC1, 
PC2 only in the UK-Wellcome Trust Case-Control Consortium-2 
and Germany-Wellcome Trust Case-Control Consortium-2 stud-
ies; Table I in the online-only Data Supplement). We meta-ana-
lyzed the 4 cohorts using a fixed-effects inverse variance-weighted 
method, as implemented in METAL.15 We first performed analyses 
using an additive model and then under dominant and recessive 
models.
WMH Volumes Analysis
The association between WMH volume and each autosomal SNP 
was determined by performing linear regression of WMH vol-
ume on genotype dosages using PLINK version 1.07.13 SNPs with 
PLINK INFO (information content metric) score >0.7 or mean al-
lele frequency <0.01 were removed from further analyses. We used 
genomic inflation to evaluate inflation of test statistics in each cen-
ter.16 Results across all centers were combined using a fixed-effects 
inverse variance-weighted method using METAL.15 Heterogeneity 
was assessed using Cochran q statistic. After the meta-analysis, we 
considered only SNPs present in >12 centers, and with heterogene-
ity P>0.001, for analysis.
NOTCH3 SNPs Analyzed and Assessment of 
Statistical Significance
In each analysis, we considered all SNPs within the NOTCH3 gene, 
and within 50-kb upstream and downstream of the coding region. A 
total of 381 SNPs from the 1000 genomes population with mean allele 
frequency >0.01 were included in the analysis. We used the Galwey 
method to estimate the effective number of independent SNPs in the 
region,17 based on the linkage disequilibrium patterns from European 
individuals in the 1000 genomes population.14 This method has 
been shown to give the best agreement with random permutations. 
Using the method, we estimated there to be 34 effective independent 
SNPs in the region. Therefore, we set our P value threshold for each 
analysis to P<0.0015. Power calculations were conducted using the 
Genetic Power Calculator for a case–control study of discrete traits 
under an additive disease risk model and a disease prevalence of 0.2% 
for lacunar stroke.18
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Results
Lacunar Stroke Analyses
We first tested for an association of any NOTCH3 SNP with 
lacunar stroke under an additive model. No SNP met our cri-
teria for statistical significance for association with lacunar 
stroke. Results for all SNPs in the region by chromosomal 
position are given in Figure 1A.
We then performed secondary analyses under recessive and 
dominant models. Again, none of these SNPs met our criteria 
for statistical significance (Figure IA and IB in the online-only 
Data Supplement). All SNPs had P>0.005 in all analyses.
We next tested for association of any NOTCH3 SNP in those 
patients with lacunar stroke who also had confluent leukoaraio-
sis or multiple lacunar infarcts (n=717) under an additive model. 
No SNP met our criteria for statistical significance for associa-
tion with lacunar stroke with confluent leukoaraiosis or multiple 
lacunar infarcts (Figure 1B). The associations for the SNPs that 
were identified in previous studies are given in the Table. Power 
calculations showed that we had >95% power to replicate these 
findings (Table III in the online-only Data Supplement).
Secondary analyses under recessive and dominant models 
also revealed no significant associations (Figure IIA and IIB 
in the online-only Data Supplement). All SNPs had P>0.005 
in all analyses.
WMH Volumes Analysis
Similarly, no SNP met our criteria for statistical significance 
for association with WMH volumes. Results for all SNPs in 
Figure 1. Association of common NOTCH3 variants with lacunar stroke (A) and lacunar stroke with leukoaraiosis or multiple lacunar 
infarcts (B). SNP indicates single nucleotide polymorphism.
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the region by genomic position are given in Figure 2. Forest 
plots showing the associations of rs10404382, rs1043994, 
rs10423702, and rs1043997 with WMH per cohort are 
shown in the Figure IIIA–IIID in the online-only Data 
Supplement.
We repeated the latter analysis in only hypertensive sub-
jects (n=2466), but again none of the SNPs met our criteria 
for statistical significance (Figure IV in the online-only Data 
Supplement).
Discussion
Mutations in the NOTCH3 gene cause CADASIL, a heredi-
tary form of SVD. Common variants in the NOTCH3 gene 
have been suggested to also confer risk of sporadic SVD. To 
test this hypothesis, we analyzed NOTCH3 in an imputed 
genome-wide association study data set of 1350 cases and 
7397 controls. We found no evidence that common variants in 
notch 3 associated with risk of lacunar stroke or WMH.
Our observation is in contrast to a recent study in a commu-
nity-dwelling elderly cohort, the Austrian Stroke Prevention 
study, which found 4 common variants at the NOTCH3 gene 
to be associated with the presence of WMH although only in 
hypertensive subjects.5 The SNP that showed the strongest 
association, rs10404382, was replicated within the Cohorts 
for Heart and Ageing Research in Genomic Epidemiology 
(CHARGE) Consortium. The associations found in the 
Austrian Stroke Prevention study were all confined to hyper-
tensive subjects. In the present study, we failed to replicate 
any of these findings in the present study, even when only 
hypertensive patients were studied. There might be several 
Figure 2. Association of common NOTCH3 variants with white matter hyperintensity volumes. SNP indicates single nucleotide polymorphism.
Table.  Association of Single Nucleotide Polymorphisms Reported in Previous Publications With 
WMH and Lacunar Stroke
WMH Lacunar Stroke
Lacunar Stroke With 
Leukoaraiosis or Multiple 
Lacunar Infarcts
MAF OR (95% CI)* P Value OR (95% CI)* P Value OR (95% CI)* P Value
Schmidt et al5
  rs10404382 0.12 1.04 (0.97–0.11) 0.33 1.08 (0.92–1.26) 0.36 1.05 (0.87–1.27) 0.61
  rs1043994 0.12 1.03 (0.96–1.11) 0.34 1.08 (0.92–1.26) 0.33 1.06 (0.88–1.29) 0.54
  rs10423702 0.12 1.04 (0.97–1.11) 0.31 1.07 (0.92–1.25) 0.39 1.05 (0.87–1.27) 0.63
  rs1043997 0.13 1.04 (0.97–1.11) 0.23 1.10 (0.95–1.28) 0.20 1.10 (0.91–1.32) 0.31
Ross et al7
  rs78501403 <0.01 † … † … † …
  rs61749020 0.02 † … 1.32 (0.83–2.10) 0.25 1.31 (0.75–2.29) 0.33
  rs3815188 0.22 1.02 (0.95–1.09) 0.59 1.11 (0.68–1.81) 0.66 1.31 (0.73–2.35) 0.37
CI indicates confidence interval; MAF, mean allele frequency; OR, odds ratio; and WMH, white matter hyperintensity.
*The reported associations are adjusted for age, sex, and the first 2 ancestry informative principal components.
†These variants were not genotyped in the specific populations because of a too low MAF.
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explanations for the discrepancy between the results of the 
Austrian Stroke Prevention study and the present study. First, 
our negative finding might be because of a type II error. The 4 
SNPs associated with the presence of WMH in hypertensive 
patients had an odds ratio between 2.1 and 3.2. We performed 
power calculations, and we had an estimated 100% power to 
detect these associations in our study (Table III in the online-
only Data Supplement). This makes type II error unlikely.
Second, there are differences in the populations studied. 
WMH lesion volume in our study was measured in clinical 
ischemic stroke populations, whereas the populations in the 
Austrian Stroke Prevention study and the CHARGE con-
sortium were community-dwelling elderly free from stroke. 
WMH are more frequent in patients with a history of stroke 
than in healthy age-matched individuals.19 It might be that the 
underlying pathology of WMH differs between patients with 
a history of stroke and community-dwelling elderly free from 
stroke. However, it is likely that, at least to some extent, there 
is an overlap in pathology because the WMH-associated locus 
17q25, which was previously identified in the CHARGE con-
sortium, was successfully replicated in the WMH populations 
used in the present study.11
Third, methods to assess WMH volume differed between 
studies. Grading of WMH was done in a similar manner in the 
present study and Austrian Stroke Prevention study because 
both used the Fazekas scale and the same cutoff for the pres-
ence of WMH.
WMH volume measurements in the present study were 
done using a similar semiautomatic method in all cohorts, 
with a good agreement between the 2 main reading centers 
(intraclass correlation coefficient, 0.95; 95% confidence inter-
val, 0.91–0.97; n=50). Also in the Austrian Stroke Prevention 
study, a semiautomatic method was used to measure the 
WMH volume. In the CHARGE consortium, WMH volume 
measurements were done using 2 different approaches; in 
most cohorts, either an automatic or a semiautomatic method 
is used, but in some cohorts, a semiquantitative rating scale 
was used.
Fourth, statistical analysis differed between the studies. In 
the Austrian Stroke Prevention, analyses were adjusted for 
several potential confounding risk factors: age, sex, diabetes 
mellitus, and cardiac disease. We repeated the analysis for 
association with the 4 SNPs detected in the previous study, 
adjusted for age, sex, hypertension, and diabetes mellitus in 
a subset of the patients with lacunar stroke and available data 
on hypertension and diabetes mellitus status (Table IV in the 
online-only Data Supplement). The additional adjustment 
for hypertension and diabetes mellitus did not significantly 
change the estimates. In addition, population structure is an 
important source of confounding to account for in genetic 
association studies.12 In contrast to the analysis reported to 
be done in Austrian Stroke Prevention study and its replica-
tion in CHARGE, we accounted for population structure in 
our analysis by including 2 ancestry informative PCs in every 
analysis.
Furthermore, we applied a correction for multiple testing in 
the analysis of the present study, based on the effective number 
of independent SNPs in the studied region (Galwey method).17 
In the Austrian Stroke Prevention study, no correction for 
multiple testing was used in their analyses, which enhances 
the possibility of false-positive findings.
One other study investigated the association between com-
mon NOTCH3 variants and ischemic stroke and revealed an 
association for 1 SNP, rs78501403.7 Unfortunately, we could 
not investigate this SNP in our study because the minor allele 
frequency of this SNP is generally <0.01% in white popu-
lations and therefore the SNP was not present in the 1000 
genomes population to which we imputed our data to.14 
Surprisingly, this SNP had a minor allele frequency of 3.3% 
in the white population in this previous study. Consistent with 
our finding, 1 previous study in lacunar stroke found no asso-
ciation between 2 common NOTCH3 SNPs and the presence 
of WMH.6
There are several limitations in this study. We used the 
approach of genotyping and then imputing all cohorts to the 
1000 genomes population. Although this method provides 
good performance for identifying common variants, the qual-
ity of imputation can drop at mean allele frequency <5%, 
meaning we cannot rule out associations at these frequencies. 
Similarly, the size of some of the WMH cohorts was small, 
meaning low-frequency variants could not be assessed in this 
analysis.
In summary, our results do not support a role for common 
NOTCH3 variation in the risk of sporadic SVD.
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Cohorts description 
 
UK Young Lacunar Stroke DNA Study (DNA Lacunar) 
DNA Lacunar is a multicentre cohort study, which constitutes a large DNA resource of 
young patients with well phenotyped lacunar stroke and stroke-free community controls. 
Between 2005 and 2012, 1030 white patients of European ancestry with lacunar stroke, aged 
< 70 years, were recruited from 72 specialist stroke centres throughout the UK. All patients 
underwent brain MRI, imaging of the carotid arteries and ECG. Echocardiography was 
performed when appropriate. All MRI’s and clinical histories were reviewed centrally by one 
experienced stroke physician. 
970 Unrelated Caucasian controls, free of clinical cerebrovascular disease, were obtained by 
random sampling from general practice lists from the same geographical location as the 
patients. Sampling was stratified for age and sex. 
 
Wellcome Trust Case-Control Consortium 2 (WTCCC2)  
The WTCCC2 samples were genotyped as part of the WTCCC 2 ischemic stroke study. 
Stroke cases were recruited from three centres in the UK (St. George's University London, 
Oxford and Edinburgh) and one centre in Germany, University and Klinikum Großhadern, 
Ludwig-Maximilians-University, Munich 
WTCCC2-UK: The St George’s Stroke Study consecutively recruited ischemic stroke patients 
attending cerebrovascular services in London between 1995 and 2008. All patients had 
clinically relevant diagnostic workup performed, including brain imaging with computed 
tomography (CT) and/or magnetic resonance imaging (MRI) as well as ancillary diagnostic 
investigations including duplex ultrasonography of the carotid and vertebral arteries, 
echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests. The Oxford Vascular Study recruited patients with acute ischemic 
stroke or transient ischemic attack (TIA) with evidence of infarction on brain imaging 
between 2002 and 2008 as part of a population-based stud. All cases were phenotyped by one 
experienced stroke neurologist with review of original imaging. The Edinburgh Stroke Study 
prospectively recruited consecutive stroke inpatients and outpatients between 2002 and 2005. 
An experienced stroke physician assessed each patient as soon as possible after the stroke, 
prospectively recording demographic and clinical details, including vascular risk factors and 
results of brain imaging and other investigations 
WTCCC2-Germany: The Munich study recruited consecutively between 2002 and 2008, 
from a single Stroke Unit with a high rate of MR imaging (>80%) (n=1383). All subjects 
were over 18 years of age, of self-reported European ancestry and with a diagnosis of 
ischemic stroke classified according to TOAST by an experienced neurologist or stroke 
physician. All patients had brain imaging as well as ancillary diagnostic investigations where 
clinically relevant. 
Controls for the UK samples were drawn from shared WTCCC controls obtained from the 
1958 Birth Cohort. This is a prospectively collected cohort of individuals born in 1958 
(http://www.b58cgene.sgul.ac.uk/), and ascertained as part of the national child development 
study (http://www.cls.ioe.ac.uk/studies.asp?section=000100020003). Data from this cohort 
are available as a common control set for a number of genetic and epidemiological studies. 
For the German samples controls were Caucasians of German origin participating into the 
population KORAgen study (www.gsf.de/kora/en/english.html). This survey represents a 
gender- and age stratified random sample of all German residents of the Augsburg area and 
consists of individuals 25 to 74 years of age, with about 300 subjects for each 10-year 
increment. All controls were free of a history of stroke or transient ischemic attack. 
 
Leuven Stroke Study 
Patients with cerebral ischemia, defined as a clinical stroke with imaging confirmation or a 
TIA with a new ischemic lesion on diffusion weighted MRI, who were admitted to the Stroke 
Unit of the University Hospitals in Leuven were enrolled. All patients underwent brain 
imaging and a standardized protocol including carotid ultrasound or CT angiography and 
cardiac examination (echocardiography and Holter monitoring) in all patients. 
Control individuals were selected from the same population and were either spouses of 
patients with multiple sclerosis, amyotrophic lateral sclerosis or stroke or healthy community 
dwelling subjects partially from the Leuven University Gerontology Database. Controls 
either confirmed they never had a stroke or TIA or responded negative to any item of the 
Verification of Stroke Free Status questionnaire. 
 
Besta Stroke Study (Milano) 
This study includes consecutive Italian patients referred to Besta Institute from 2000 to 2009 
with stroke and included in the Besta Cerebrovascular Diseases Registry (CEDIR). Ischemic 
stroke cases, first ever or recurrent, confirmed on brain imaging, were selected for this study. 
An experienced stroke neurologist assessed all cases. 
 
St Georges University of London (SGUL) 
This study recruited patients attending cerebrovascular services at St. George’s Hospital, 
London between 2007-2011. All patients had clinically relevant diagnostic workup 
performed, including brain imaging with magnetic resonance imaging (MRI) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and 
vertebral arteries, echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests 
 
GENESIS 
This study recruited patients attending cerebrovascular services at St. George’s Hospital, 
London between 2011-2013. All patients had clinically relevant diagnostic workup 
performed, including brain imaging with magnetic resonance imaging (MRI) as well as 
ancillary diagnostic investigations including duplex ultrasonography of the carotid and 
vertebral arteries, echocardiography, 
Holter monitoring, magnetic resonance angiography (MRA), CT-angiography 
(CTA) and blood tests 
 
Massachusetts General Hospital (MGH) 
Cases presenting with ischemic stroke and admitted to the Massachusetts General Hospital 
(MGH) Stroke Unit through the Emergency Department, or evaluated in the MGH Neurology 
outpatient clinics, as well as on the inpatient Medical and Vascular Surgical services from 
January 2003 to July 2008. Ischemic stroke was defined as either (1) a radiographically 
proven (head CT or MRI) infarct associated with the appropriate clinical stroke syndrome, or 
(2) a fixed neurological deficit persisting more than 24 hours, consistent with a vascular 
pattern of involvement and without radiographic evidence of demyelinating or other non-
vascular disease. All subjects were evaluated by a neurologist upon presentation and clinical 
and laboratory data were collected during the admission for qualifying ischemic stroke event.  
All patients had acute brain imaging as well as ancillary diagnostic investigations: cervical 
and intracranial vessel imaging using CT or MR angiography (75%), cervical ultrasound 
(24%), echocardiography (86%), and Holter monitoring (16%).  
 
Australian Stroke Genetics Collaborative (ASGC)  
Stroke cases comprised European-ancestry patients admitted to four clinical centres across 
Australia (The Neurosciences Department at Gosford Hospital, Gosford, New South Wales 
(NSW); the Neurology Department at John Hunter Hospital, Newcastle, NSW; The Queen 
Elizabeth Hospital, Adelaide; and the Royal Perth Hospital, Perth) between 2003 and 2008. 
Stroke was defined by WHO criteria as a sudden focal neurologic deficit of vascular origin, 
lasting more than 24 hours and confirmed by brain imaging. Other investigative tests such as 
electrocardiogram, carotid Doppler and trans-oesophageal echocardiogram were conducted to 
define stroke aetiology as clinically appropriate.  
Ischemic Stroke Genetics Study (ISGS) 
Ischemic Stroke Genetics Study (ISGS) was a 5-center, prospective, case-control study of 
first-ever ischemic stroke cases. All affected individuals had WHO-defined stroke confirmed 
by a study neurologist to be ischemic on the basis of head CT or brain MRI. Peripheral blood 
DNA samples were collected between May 2003 and September 2008.  
 
Sibling with Ischaemic Stroke Study (SWISS) 
This is a prospective, multicentre study of sibling pairs with first-ever or recurrent ischemic 
stroke. Probands were recruited from 70 clinical centres across the US and Canada. Ischemic 
stroke affected and unaffected siblings were recruited primarily using proband-initiated 
contact. All affected individuals had WHO-defined stroke confirmed by a study neurologist 
to be ischemic on the basis of brain imaging. Peripheral blood DNA samples were collected 
between October 2000 and December 2009.  
  
Specific acknowledgements for UK Young Lacunar Stroke DNA Study (DNA Lacunar)  
Study managers: Josie Monaghan; Alan Zanich, Samantha Febrey, Eithne Smith, Jenny 
Lennon, St George’s University of London 
 
Participating centres (number of enrolled patients per centre; local investigators): 
Aberdeen Royal Infirmary, Aberdeen (12; Mary Macleod). Addenbrooke’s Hospital, 
Cambridge (54; Jean-Claude Baron, Elizabeth Warburton, Diana J Day, Julie White). 
Airedale General Hospital, Steeton (4; Samantha Mawer). Barnsley Hospital, Barnsley (3; 
Mohammad Albazzaz, Pravin Torane, Keith Elliott, Kay Hawley). Bart’s and the London, 
London (2; Patrick Gompertz). Basingstoke and North Hampshire Hospital, Basingstoke (13; 
Elio Giallombardo, Deborah Dellafera). Blackpool Victoria Hospital, Blackpool (11; Mark 
O'Donnell). Bradford Royal Infirmary, Bradford (1; Chris Patterson). Bristol Royal 
Infirmary, Bristol (8; Sarah Caine). Charing Cross Hospital, London (12; Pankaj Sharma). 
Cheltenham General and Gloucester Royal Hospitals, Cheltenham and Gloucester (10; 
Dipankar Dutta). Chesterfield Royal Hospital, Chesterfield (4; Sunil Punnoose, Mahmud 
Sajid). Countess of Chester Hospital, Chester (22; Kausik Chatterjee). Derriford Hospital, 
Plymouth (4; Azlisham Mohd Nor). Dorset County Hospital NHS Foundation Trust, 
Dorchester (6; Rob Williams). East Kent Hospitals University NHS Foundation Trust, Kent 
(22; Hardeep Baht, Guna Gunathilagan). Eastbourne District General Hospital, Eastbourne 
(4; Conrad Athulathmudali). Frenchay Hospital, Bristol (1; Neil Baldwin). Frimley Park 
Hospital NHS Foundation Trust, Frimley (6; Brian Clarke). Guy’s and St Thomas’ Hospital, 
London (14; Tony Rudd). Institute of Neurology, London (25; Martin Brown). James Paget 
University Hospital, Great Yarmouth (1; Peter Harrison). King's College Hospital, London 
(16; Lalit Kalra). Leeds Teaching Hospitals NHS Trust, London (125; Ahamad Hassan). 
Leicester General Hospital and Royal Infirmary, Leicester (9; Tom Robinson, Amit Mistri). 
Luton and Dunstable NHSFT University Hospital, Luton (16; Lakshmanan Sekaran, 
Sakthivel Sethuraman, Frances Justin). Maidstone andTunbridge Wells NHS Trust (3; Peter 
Maskell). Mayday University Hospital, Croydon (14; Enas Lawrence). Medway Maritime 
Hospital, Gillingham (5; Sam Sanmuganathan). Milton Keynes Hospital, Milton Keynes (1; 
Yaw Duodu). Musgrove Park Hospital, Taunton (9; Malik Hussain). Newcastle Hospitals 
NHS Foundation Trust, Newcastle upon Tyne (12; Gary Ford). Ninewells Hospital, Dundee 
(5; Ronald MacWalter). North Devon District Hospital, Barnstaple (8; Mervyn Dent). 
Nottingham University Hospitals, Nottingham (17; Philip Bath, Fiona Hammonds). Perth 
Royal Infirmary, Perth (2; Stuart Johnston). Peterborough City Hospital, Peterborough (1; 
Peter Owusu-Agyei). Queen Elizabeth Hospital, Gateshead (5; Tim Cassidy, Maria Bokhari). 
Radcliffe Infirmary, Oxford (5; Peter Rothwell). Rochdale Infirmary, Rochdale (4; Robert 
Namushi). Rotherham General Hospital, Rotherham (1; James Okwera). Royal Cornwall 
Hospitals NHS Trust, Truro (11; Frances Harrington, Gillian Courtauld). Royal Devon and 
Exeter Hospital, Exeter (22; Martin James). Royal Hallamshire Hospital, Sheffield (1; 
Graham Venables). Royal Liverpool University Hospital and Broadgreen Hospital, Liverpool 
(9; Aravind Manoj). Royal Preston Hospital, Preston (18; Shuja Punekar). Royal Surrey 
County Hospital, Guildford (23; Adrian Blight, Kath Pasco). Royal Sussex County Hospital, 
Brighton (14; Chakravarthi Rajkumar, Joanna Breeds). Royal United Hospital, Bath (6; 
Louise Shaw, Barbara Madigan). Salford Royal Hospital, Salford (16; Jane Molloy). 
Southampton General Hospital, Southampton (1; Giles Durward). Southend Hospital, 
Westcliff-on-Sea (26; Paul Guyler). Southern General Hospital, Glasgow (34; Keith Muir, 
Wilma Smith). St George’s Hospital, London (108; Hugh Markus). St Helier Hospital, 
Carshalton (10; Val Jones). Stepping Hill Hospital, Stockport (4; Shivakumar 
Krishnamoorthy). Sunderland Royal Hospital, Sunderland (1; Nikhil Majumdar). The Royal 
Bournemouth Hospital, Bournemouth (15; Damian Jenkinson). The Walton Centre, Liverpool 
(15; Richard White). Torbay Hospital, Torquay (19; Debs Kelly). University Hospital 
Aintree, Liverpool (19; Ramesh Durairaj). University Hospital of North Staffordshire, Stoke-
on-trent (16; David Wilcock). Wansbeck General Hospital and North Tyneside Hospital, 
Ashington and North Shields (6; Christopher Price). West Cumberland Hospital, Whitehaven 
(6; Olu Orugun, Rachel Glover). West Hertfordshire Hospital, Watford (20; David Collas). 
Western General Hospital, Edinburgh (12; Cathie Sudlow). Western Infirmary, Glasgow (33; 
Kennedy R. Lees, Jesse Dawson). Wycombe Hospital and Stoke Mandeville, High Wycombe 
(20; Dennis Briley and Matthew Burn). Yeovil District Hospital, Yeovil (46; Khalid Rashed). 
York Teaching Hospital, York (1; John Coyle).  
 
  
Table I Lacunar stroke study population 
 
Centre Country N Mean age (sd) % Male 
DNA Lacunar patients UK 1013 57.2 (9.5) 720 (71.1) 
DNA Lacunar controls   970 59.7 (4.3) 510 (52.6%) 
Germany WTCCC2 patients Germany 37 65.2 (9.6) 28 (75.7) 
Germany WTCCC2 controls   797 - 409 (51.3) 
UK WTCCC2 patients UK 258 69.1 (11.7) 109 (42.2) 
UK WTCCC2 controls   5175 - 2564 (49.5) 
Leuven patients Belgium 42 65.5 (13.9) 29 (69%) 
Leuven controls   455 55.7 (14.5) 212 (46.6%) 
Overall patients  1350   
Overall controls   7397     
Abbreviations: DNA Lacunar, UK Young Lacunar Stroke DNA Study; Germany WTCCC2, The 
Wellcome Trust Case-Control Consortium II Munich; UK WTCCC2, The Wellcome Trust Case-
Control Consortium II UK; Leuven, Leuven Stroke Study  
Table II WMH study populations 
 
Centre Country N Mean age (sd) % Male % Hypertensive 
Milano Italy 151 57 (14) 60% 57% 
WTCCC2-Edinburgh UK 64 68 (13) 50% 72% 
WTCCC2-Munich FLAIR Germany 447 66 (12) 66% 72% 
WTCCC2-Munich T2 Germany 203 67 (12) 55% 67% 
WTCCC2-Oxford Flair UK 65 65 (15) 54% 65% 
WTCCC2-Oxford T2 UK 75 67 (13) 59% 68% 
WTCCC2-SGUL UK 323 70 (14) 63% 77% 
GENESIS 1  UK 121 67 (14) 67% 62% 
GENESIS 2 UK 228 69 (15) 58% 76% 
SGUL 1 UK 70 70 (13) 61% 61% 
SGUL 2 UK 57 68 (14) 58% 72% 
DNA Lacunar UK 303 57 (9) 72% 68% 
Leuven Belgium 361 66 (15) 58% 59% 
MGH-Affymetrix US 476 67 (14) 60% 64% 
MGH-Omni US 84 64 (15) 63% 68% 
MGH-Illumina US 228 66 (15) 64% 61% 
ASGC Australia 96 65 (13) 57% 77% 
ISGS US 207 68 (14) 62% 61% 
SWISS US 111 66 (11) 48% 74% 
Overall   3670       
Abbreviations: Milano, Besta Stroke Register; WTCCC2, The Wellcome Trust Case-Control 
Consortium II; GENESIS, Genetic Risk factors for Leukoaraiosis study; SGUL, St Georges 
University of London; DNA Lacunar, UK Young Lacunar Stroke DNA Study; Leuven, Leuven 
Stroke Study; MGH, Massachusetts General Hospital; ASGC, Australian Stroke Genetics 
Collaborative; ISGS, Ischemic Stroke Genetics Study; SWISS, Sibling with Ischaemic Stroke Study  
  
Table III Estimated power in the present study to detect an association of the common SNPs 
in NOTCH3 with lacunar stroke 
  MAF OR*  
Estimated 
power 
n cases needed 
for 80% power 
rs10404382 0.12 1.75 >99% 236 
rs1043994 0.12 1.68 >99% 282 
rs10423702 0.12 1.70 >99% 267 
rs1043997 0.13 1.48 >99% 531 
Abbreviations: MAF, minor allele frequency; OR, odds ratio 
* Odds ratio’s for the presence of white matter hyperintensities, reported in the study by Schmidt et 
al.1  
Power calculations were conducted using the Genetic Power Calculator2 for a case-control 
study of discrete traits under an additive disease risk model and a disease prevalence of 0.2% 
for lacunar stroke.  
  
Table IV Association of four common SNPs in NOTCH3 in DNA lacunar, adjusted for 
principal components 1 and 2 and age and sex (model 1) and adjusted for the factors in model 
1 plus hypertension and diabetes (model 2). 
 
 
  
 
 
  Model 1  Model 2 
 MAF  OR (95% CI) p  OR (95% CI) p 
rs10404382 0.12  1.03 (0.84-1.27) 0.78  1.03 (0.83-1.27) 0.80 
rs1043994 0.12  1.01 (0.83-1.25) 0.90  1.01 (0.82-1.25) 0.91 
rs10423702 0.12  1.03 (0.84-1.27) 0.78  1.03 (0.83-1.27) 0.80 
rs1043997 0.13  0.99 (0.81-1.21) 0.93  0.99 (0.81-1.21) 0.93 
Figure I Association of common NOTCH3 variants with lacunar stroke under dominant (A) 
and recessive (B) models by genomic position 
 
A 
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Figure II Association of common NOTCH3 variants with lacunar stroke with leukoaraiosis 
under dominant (A) and recessive (B) models by genomic position 
 
A 
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Figure III-A Forest plot for the association of the single nucleotide polymorphism 
rs10404382 with WMH 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator. 
  
Cochran’s Q = 22.8, p=0.20, 
I2=21.0% 
Figure III-B Forest plot for the association of the single nucleotide polymorphism rs1043994 
with WMH 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator. 
  
Cochran’s Q = 22.6, p=0.21, 
I2=20.4% 
Figure III-C Forest plot for the association of the single nucleotide polymorphism 
rs10423702 with WMH 
 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator. 
  
Cochran’s Q = 23.0, p=0.19, 
I2=21.6% 
Figure III-D Forest plot for the association of the single nucleotide polymorphism rs1043997 
with WMH 
 
 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator. 
  
Cochran’s Q = 23.4, p=0.17, 
I2=23.2% 
Figure IV Forest plot for the association of the single nucleotide polymorphism rs10404382 
with WMH in only hypertensive patients. 
 
The size of the box is inversely proportional to the estimate variance of the effect estimator. 
 
  
Cochran’s Q = 21.8, p=0.24, 
I2=17.4% 
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